Expert dermatologists discuss the use of nonsteroidal treatment formulations for the treatment of AD, focusing on a topical treatment, tapinarof cream, 1%.
This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD.
In the discussion on iterative progress in atopic dermatitis, the emphasis is on moving beyond steroids and non-selective therapies. The focus shifts to non-steroidal topical options, particularly emerging classes and therapies. A topical Janus kinase (JAK) inhibitor, ruxolitinib cream, is highlighted for its efficacy in mild to moderate disease, but concerns arise due to a box warning. Emerging therapies in the phosphodiesterase 4 (PDE4) class, such as crisaborole and the promising topical apremilast, are discussed.
The conversation turns to the aryl hydrocarbon receptor (AHR), with insights provided on tapinarof—a new topical agent that uniquely binds to AHR. Tapinarof suppresses inflammatory cytokines, modulates skin barrier protein expression, and exhibits antioxidant activity. Excitement surrounds tapinarof's potential to connect inflammation, the barrier, and antioxidant components differently from traditional treatments targeting the immune aspect.
Tapinarof's uniqueness lies in its comprehensive approach to controlling atopic dermatitis. The discussion highlights its potential in psoriasis and its ability to induce a remittative effect, allowing patients to take breaks during periods of skin quiescence. The evolving landscape of atopic dermatitis treatments is acknowledged, emphasizing the importance of comprehensive approaches addressing both immune and non-immune aspects of the condition. The potential for tapinarof to revolutionize long-term treatment strategies and improve patient compliance is a key point of interest in the discussion.
Video synopsis is AI-generated and reviewed by Dermatology Times editorial staff.